In their study examining the effects of Temozolomide treatment with or without anti-PD-L1, Miyakazi et al. demonstrated that infiltration of CD163+ cells increased 2.7× in recurrent GBM specimens from patients treated with immunotherapy, as opposed to a very slight 1.1× increase observed in a pair of specimens from GBM patients treated with only standard therapy [73] (Table 1). The gene discussed is CD163; the disease is glioblastoma.